How to buy Personalis stock | 27.67

Personalis, Inc is a diagnostics & research business based in the US. Personalis shares (PSNL) are listed on the NASDAQ and all prices are listed in US Dollars. Personalis employs 181 staff and has a trailing 12-month revenue of around USD$76.6 million.

How to buy shares in Personalis

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Personalis. Find the stock by name or ticker symbol: PSNL. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Personalis reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$27.67, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Personalis, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Personalis. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Personalis share price

Use our graph to track the performance of PSNL stocks over time.

Personalis shares at a glance

• Key figures

Information last updated 2020-11-25.

Latest market close	USD$27.67
52-week range	USD$4.27 - USD$31.8
50-day moving average	USD$27.2139
200-day moving average	USD$19.922
Wall St. target price	USD$30.57
PE ratio	53.9512
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-4.736

Buy Personalis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Personalis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Personalis, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Personalis price performance over time

Historical closes compared with the close of $27.67 from 2020-11-16

1 week (2020-11-20)	N/A
1 month (2020-10-28)	N/A
3 months (2020-08-28)	N/A
6 months (2020-05-28)	N/A

1 year (2019-11-27)	N/A
2 years (2018-11-27)	N/A
3 years (2017-11-27)	N/A
5 years (2015-11-27)	N/A

Is Personalis under- or over-valued?

Valuing Personalis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Personalis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Personalis's P/E ratio

Personalis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 54x. In other words, Personalis shares trade at around 54x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Personalis financials

Revenue TTM	USD$76.6 million
Gross profit TTM	USD$22.1 million
Return on assets TTM	-11.01%
Return on equity TTM	-21.96%
Profit margin	-45.13%
Book value	$3.577
Market capitalisation	USD$984.2 million

TTM: trailing 12 months

Shorting Personalis shares

There are currently 1.7 million Personalis shares held short by investors – that's known as Personalis's "short interest". This figure is 14.7% up from 1.5 million last month.

There are a few different ways that this level of interest in shorting Personalis shares can be evaluated.

Personalis's "short interest ratio" (SIR)

Personalis's "short interest ratio" (SIR) is the quantity of Personalis shares currently shorted divided by the average quantity of Personalis shares traded daily (recently around 774128.7037037). Personalis's SIR currently stands at 2.16. In other words for every 100,000 Personalis shares traded daily on the market, roughly 2160 shares are currently held short.

However Personalis's short interest can also be evaluated against the total number of Personalis shares, or, against the total number of tradable Personalis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Personalis's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Personalis shares in existence, roughly 30 shares are currently held short) or 0.0487% of the tradable shares (for every 100,000 tradable Personalis shares, roughly 49 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Personalis.

Find out more about how you can short Personalis stock.

Personalis share dividends

We're not expecting Personalis to pay a dividend over the next 12 months.

Personalis overview

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. Personalis, Inc. has partnership with Berry Genomics. The company was founded in 2011 and is headquartered in Menlo Park, California.

Frequently asked questions

• What percentage of Personalis is owned by insiders or institutions?

  Currently 1.9% of Personalis shares are held by insiders and 84.33% by institutions.

• How many people work for Personalis?

  Latest data suggests 181 work at Personalis.

• When does the fiscal year end for Personalis?

  Personalis's fiscal year ends in December.

• Where is Personalis based?

  Personalis's address is: 1330 O?Brien Drive, Menlo Park, CA, United States, 94025

• What is Personalis's ISIN number?

  Personalis's international securities identification number is: US71535D1063

• What is Personalis's CUSIP number?

  Personalis's Committee on Uniform Securities Identification Procedures number is: 71535D106